Biotech firms often find themselves at the mercy of regulators and their tough approval process before new medications can reach the market. But the Food and Drug Administration has now set up a separate system to fast track the approval of priority drugs in the pipeline, benefiting the companies along with the potential patients.
Morgan Brennan has more.
